G1 Therapeutics, Inc.

NasdaqGS:GTHX Stock Report

Market Cap: US$378.2m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

G1 Therapeutics Future Growth

Future criteria checks 6/6

G1 Therapeutics is forecast to grow earnings and revenue by 67.2% and 36.1% per annum respectively. EPS is expected to grow by 68.3% per annum. Return on equity is forecast to be 33.4% in 3 years.

Key information

67.2%

Earnings growth rate

68.3%

EPS growth rate

Biotechs earnings growth26.8%
Revenue growth rate36.1%
Future return on equity33.4%
Analyst coverage

Low

Last updated18 Sep 2024

Recent future growth updates

G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 04
G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Recent updates

There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise

Jul 26
There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise

G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty

Jun 24

Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why

Jun 07
Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

May 28
Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 04
G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape

Mar 22

Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge

Feb 27
Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge

Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

Feb 06
Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry

Jan 04
G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

Jun 08
Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)

May 08
New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)

The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts

Nov 04
The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts

G1 Therapeutics: Catalysts Stacking

Oct 20

G1 Therapeutics: Building A Franchise

Sep 29

Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)

Aug 04
Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)

G1 Therapeutics Q2 2022 Earnings Preview

Aug 02

G1 Therapeutics: Take Advantage Of The November Data

Jul 22

Earnings and Revenue Growth Forecasts

NasdaqGS:GTHX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20264773029654873
12/31/202589-11-563
12/31/202471-24-30-151
6/30/202458-45-38-38N/A
3/31/202484-31-18-18N/A
12/31/202383-48-38-38N/A
9/30/202378-71-56-56N/A
6/30/202389-78-67-67N/A
3/31/202357-126-120-119N/A
12/31/202251-148-129-129N/A
9/30/202247-154-133-133N/A
6/30/202228-171-146-145N/A
3/31/202224-171-143-143N/A
12/31/202131-148-132-132N/A
9/30/202142-134-129-129N/A
6/30/202164-103-91-91N/A
3/31/202160-95-84-84N/A
12/31/202045-99-84-84N/A
9/30/202029-109-83-82N/A
6/30/20202-130-113-111N/A
3/31/2020N/A-130-108-105N/A
12/31/2019N/A-122-102-100N/A
9/30/2019N/A-111-93-91N/A
6/30/2019N/A-99-83-82N/A
3/31/2019N/A-89-79-78N/A
12/31/2018N/A-85-75-74N/A
9/30/2018N/A-78-68-68N/A
6/30/2018N/A-74-65-65N/A
3/31/2018N/A-68N/A-59N/A
12/31/2017N/A-65N/A-51N/A
9/30/2017N/A-60N/A-45N/A
6/30/2017N/A-52N/A-37N/A
3/31/2017N/A-45N/A-29N/A
12/31/2016N/A-35N/A-25N/A
12/31/20151-22N/A-14N/A
12/31/20141-7N/A-6N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GTHX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).

Earnings vs Market: GTHX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: GTHX is expected to become profitable in the next 3 years.

Revenue vs Market: GTHX's revenue (36.1% per year) is forecast to grow faster than the US market (8.7% per year).

High Growth Revenue: GTHX's revenue (36.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: GTHX's Return on Equity is forecast to be high in 3 years time (33.4%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/09/18 21:21
End of Day Share Price 2024/09/18 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

G1 Therapeutics, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Harshita PolishettyB. Riley Securities, Inc.
Dane LeoneBTIG
Charles ButlerD. Boral Capital LLC.